

**ASX/Media Release**  
**Thursday 26<sup>th</sup> March 2009**

**PRIMA BIOMED SECURES SECOND EUROPEAN PATENT FOR CVac™  
OVARIAN CANCER TREATMENT**

Australian health care company Prima BioMed (Prima) (ASX: PRR) is pleased to announce that its subsidiary company, Cancer Vac Pty Ltd, has today been granted a patent covering the administration of Prima's ovarian cancer immunotherapy product **CVac™** by the European Patent Office.

**CVac™** is Prima BioMed's lead product. It is a therapy treatment for ovarian cancer administered post-surgery and post-chemotherapy to delay relapse and control metastases. There is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate, and currently there are no maintenance based therapy products commercially available.

The Company is making rapid progress towards commercializing **CVac™** into the global multi-billion oncology pharmacy market.

The granted patent claims represent significant value for the company because they create a potential pipeline of products, as they allow the use of any antigen to be conjugated to oxidised mannan fusion protein prior to administration to dendritic cells. Currently Prima is focusing the development of **CVac™** to target the tumour specific antigen Mucin-1, an antigen highly expressed on the surface of ovarian cancer cells.

The new patent claims also create additional value for Prima by extending the patent life of this patent application to 2018, which provides a potential four more years of revenues for the current product under development. (The previously granted patent, 659768, which provides protection for the production of the **CVac™** product will expire in 2014).

The patent will be validated in Austria, Belgium, Switzerland/Lichtenstein, Germany, Denmark, Spain, France, United Kingdom, Ireland, Italy, Luxembourg, The Netherlands and Sweden.

The new patent claims are granted under patent number 1027063, entitled "Compositions for immunotherapy". It provides for the *ex vivo* application of conjugated vaccine to patient's own dendritic cells.

**For further information please contact:**

Ata Gokyildirim  
Chairman  
Prima BioMed  
Ph: 0408 685 548

E: [ata@primabiomed.com.au](mailto:ata@primabiomed.com.au)

Website: [www.primabiomed.com.au](http://www.primabiomed.com.au)

James Moses  
Investor and Media Relations  
Mandate Corporate

Ph: 0420 991 574

E: [james@mandatecorporate.com.au](mailto:james@mandatecorporate.com.au)

## **About CVac™ Ovarian Cancer Treatment**

**CVac™** is a therapy treatment for ovarian cancer consisting of a patient's own dendritic cells primed with a tumour antigen (Mucin-1) and an adjuvant, Mannan Fusion Protein (MFP) currently being investigated in clinical trials.

MFP refers to the form in which the target protein of the **CVac™** immunotherapy is presented to the immune system. The mannan used is a chain of mannose molecules that is oxidised and linked to the cancer protein (Mucin-1). Mannan stimulates the immune system and it is the mannan that results in rapid uptake of Mucin-1 into the dendritic cells of the immune system via the mannose receptor on the cell surface. Once the MFP is inside the dendritic cell, enzymes digest the Mucin-1 and fragments of Mucin-1 are presented on the dendritic cell surface. This presentation results in the stimulation of certain cells of the immune system to target Mucin-1 on the surface of the cancer cells.

## **About Ovarian Cancer**

Ovarian cancer causes a significant burden of disease accounting for 5% of all cancer deaths and is the fifth leading cause of death in women in Canada, the US, and Europe. According to the American Cancer Society, in 2006 there were an estimated 20,000 new cases and more than 15,000 deaths from ovarian cancer in the US alone. The front-line treatment for ovarian cancer is typically a combination of a taxane and a platinum drug. An initial response rate of approximately 70 percent to this type of chemotherapy regimen can be anticipated. In spite of initial response rates, recurrence rates among ovarian cancer patients are high and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 20 percent.

## **About Prima BioMed**

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima's lead product is the **CVac™** ovarian cancer therapy treatment. It has completed two successful clinical trials and is in the final stages of US FDA approval and eventual commercialisation.

The Company's broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

*This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing and results of clinical trials, interpretation and implications of such results, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward - looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward - looking statements are expressly qualified in their entirety by this cautionary statement.*

**Prima BioMed Ltd**, Suite 1, 1233 High Street, Armadale, VIC Australia 3143

Ph: +61 (0)3 9824 5254 Fax: + 61 (0)3 9822 7735

[www.primabiomed.com.au](http://www.primabiomed.com.au)

ABN 90 009 237 889